NextCure (NASDAQ:NXTC) Downgraded to Sell Rating by Wall Street Zen

NextCure (NASDAQ:NXTC) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently commented on the stock. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of NextCure in a report on Wednesday. Finally, Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NextCure has an average rating of “Hold” and a consensus target price of $19.00.

NextCure Trading Down 2.9%

NASDAQ:NXTC opened at $5.99 on Friday. NextCure has a 1-year low of $1.55 and a 1-year high of $15.74. The firm has a market capitalization of $21.62 million, a price-to-earnings ratio of -0.35 and a beta of 1.42. The business’s 50-day moving average price is $4.43 and its two-hundred day moving average price is $9.30.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.10) by $0.23. Sell-side analysts predict that NextCure will post -7.89 earnings per share for the current year.

Hedge Funds Weigh In On NextCure

A number of large investors have recently bought and sold shares of NXTC. Ikarian Capital LLC bought a new position in NextCure in the fourth quarter valued at $3,382,000. Squadron Capital Management LLC bought a new position in NextCure during the fourth quarter worth $3,363,000. Exome Asset Management LLC acquired a new position in NextCure in the 4th quarter valued at about $2,341,000. AWM Investment Company Inc. acquired a new position in NextCure in the 4th quarter valued at about $1,665,000. Finally, Cable Car Capital LP raised its holdings in NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.